Internet Archive Scholar

Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy

Hironobu Hashimoto, Masakazu Abe, Takako Yanai, Takuhiro Yamaguchi, Sadamoto Zenda, Yosuke Uchitomi, Haruhiko Fukuda, Mikio Mori, Satoru Iwasa, Noboru Yamamoto, Yuichiro Ohe
2018 Japanese Journal of Clinical Oncology  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (138.6 kB)
https://web.archive.org/web/20190503125547/https://watermark.silverchair.com/hyy114.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAAjwwggI4BgkqhkiG9w0BBwagggIpMIICJQIBADCCAh4GCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMKoG7MSZV59q0W_bqAgEQgIIB7wqFPwJI-QopdqvlhC_orNUvvg7qQCbxzWfquBp8uCiUp-qtIi8PvheFAtdLPYyFwUiABZH__wtMlcGlYFzKMNXsAH7Ns7XI9GYmoIcj4zSCW_p5J16eZZQh7Awi4_HYX0dQ14iOhwXDlvYxgjHDNEKGiQ67_qe98vXZYFJBynQzvsminQ5-sKSmwM_b_PUdAOH4428jfkyiT0JLV_6V9fmqu9O5sL1Kbk5gpZ2wKrf5S0iU9ZNp4lIHN2fx_SQ8GpkmcGHiWGj1zD0T66ddTm_nld_kdbvTaG1o9gO9wgTS27iqK4SQ-vTOotKo-5-hjUVKJWpe12wDeJbKTT5L0fCc-iMfIclNXzBHdSUV9YUbdJlzBPr8-82boqDLJlVdbaFYuMIPi8zURJxjOTkqusA5L59aSwbjFo23H8y2UleFeWoXg5jiBSG4_PhX0iiIVBEDGlzviqcE4Sjbd3xypXB325UAYGdNSOeTnKQ5FGQVe8qMArWdqrpNnBa2XXGP33ZGePDVA59sqDTkbApV5u8GMW2-IKMkiDen7KXddqouWHj-sSaRgjlqsNLZDCINzpPZdF41uAZN8xIzAkxh7KzUx1B_D8H_3mHskydm1H0NMMlj0W3oRodHSEfH6qOx282nNDQeynVaGm-JqU1aXQ

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL. The file type is application/pdf.

doi:10.1093/jjco/hyy114 pmid:30124989 fatcat:52sshhmkwnbpjmaopmtbanlgna
Citation

Hironobu Hashimoto, Masakazu Abe, Takako Yanai, Takuhiro Yamaguchi, Sadamoto Zenda, Yosuke Uchitomi, Haruhiko Fukuda, Mikio Mori, Satoru Iwasa, Noboru Yamamoto, Yuichiro Ohe. "Study protocol for J-SUPPORT 1604 (J-FORCE): a randomized, double blind, placebo-controlled Phase III study evaluating olanzapine (5 mg) plus standard triple antiemetic therapy for prevention of chemotherapy induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy." Japanese Journal of Clinical Oncology 48.10 (2018)